Wordt geladen...
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
INTRODUCTION: Clinical evidence comparing chemotherapy and tyrosine kinase inhibitors (TKIs) as second-line therapy for epidermal growth factor receptor (EGFR) wild-type non-small-cell lung cancer (NSCLC) are conflicting. METHODS: We retrospectively reviewed stage IV EGFR wild-type NSCLC patients wh...
Bewaard in:
| Gepubliceerd in: | Onco Targets Ther |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5079695/ https://ncbi.nlm.nih.gov/pubmed/27799795 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S119341 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|